Lytix Biopharma

Equities

LYTIX

NO0010405780

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 15:45:00 16/05/2024 BST			5-day change	1st Jan Change
5.6 ^NOK	-10.83%		+2.19%	+15.23%

04-25	Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	CI
04-10	Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	MT

Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2023

May 11, 2023 at 09:17 am

Lytix Biopharma AS reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was NOK 0.375 million compared to NOK 1.51 million a year ago. Net loss was NOK 19.67 million compared to NOK 15.23 million a year ago.

Latest news about Lytix Biopharma

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	04-25	CI
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	04-10	MT
Transcript : Lytix Biopharma AS, Q4 2023 Earnings Call, Feb 29, 2024	02-29
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	01-05	MT
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology	12-11	CI
Transcript : Lytix Biopharma AS, Q3 2023 Earnings Call, Nov 09, 2023	11-09
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : Lytix Biopharma AS - Special Call	23/10/23
Lytix Biopharma AS Announces Research Council of Norway Approves Lytix?s Application for Up to NOK 14.3 Million of Non-Dilutive Financial Support from the Skattefunn	17/10/23	CI
Lytix Biopharma Secures NOK14.3 Million Research Grant for Skin Cancer Treatment	17/10/23	MT
Transcript : Lytix Biopharma AS, Q2 2023 Earnings Call, Aug 31, 2023	31/08/23
Lytix Biopharma AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/08/23	CI
Lytix Biopharma Completes Patient Enrollment for LTX-315 Trial	28/08/23	MT
Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial	28/08/23	CI
Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315	11/08/23	CI
Lytix Biopharma AS Announces Presentation of Interim Data from ATLAS-IT-05 Study at ESMO 2023	19/07/23	CI
Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Lytix Biopharma Elects New Chair	19/04/23	MT
Lytix Biopharma AS Appoints Marie Ann Roskrow as New Chairman of the Board	18/04/23	CI
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2022	16/02/23	CI
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/02/23	CI
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/11/22	CI
Lytix Biopharma Expands Clinical Trial for Skin Cancer Drug to Spain, France, Norway	14/11/22	MT

Chart Lytix Biopharma

Duration

Period

More charts

Company Profile

Lytix Biopharma AS is a Norway-based company engaged in biotechnology. The Company is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patientâs immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LYTIX BIOPHARMA	+15.23%	21.01M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research